Home
Resources
Publications
Limonin Ameliorates Ulcerative Colitis by Regulating STAT3/miR-214 Signaling Pathway

Limonin Ameliorates Ulcerative Colitis by Regulating STAT3/miR-214 Signaling Pathway

Shijia Liu, Shufang Zhang, Xiangyu Lv, Jiawei Lu, Cong Ren, Zhiqin Zeng, Lufeng Zheng, Xianke Zhou, Haiyan Fu, Dong Zhou, Yugen Chen

Int Immunopharmacol. 2019 Oct;75:105768.

PMID: 31382166

Abstract:

Ulcerative colitis (UC) is a major inflammatory bowel disease (IBD) which has become a global public health problem. Limonin is a triterpenoid extracted from citrus which possesses the capacities to against inflammations and cell apoptosis. However, the efficacy and the underlying mechanisms of limonin in the treatment of UC remain unclear. In this study, we first investigated the therapeutic effects of limonin on dextran sodiumsulfate (DSS)-induced UC in vivo by examining the changes of disease activity index (DAI), the colon length, the colon histology, and cyto/chemokine levels. We found that limonin markedly reduced DAI, intestinal damages, and the levels of pro-inflammatory cytokines, such as TNF-α and IL-6. In vitro, limonin significantly repressed the productions of pro-inflammatory cytokines in cultured normal colonic epithelial cells. Mechanistically, we demonstrated that limonin improved the prognosis of UC mainly through downregulating p-STAT3/miR-214 levels. Collectively, our results suggested that limonin was a novel therapeutic agent and it was expected to be translated into the clinic to improve the prognosis of UC.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP1180718	Limonin		1180-71-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: